Abstract
In May 2012, a group of scientists and clinicians met in Athens (Greece) to consider the relevance of ageing, longevity, exceptional longevity and related genetic and non genetic markers. During this meeting, we firstly reviewed recent epidemiological and clinical studies on ageing, longevity and exceptional longevity, briefly analyzed the ageing theories and discussed successful and unsuccessful ageing also taking into account the evolutionary perspective. Secondly, we considered the three phenotypes based on the definition of ageing, longevity and exceptional longevity and the associated biomarkers. Third, we discussed proposed treatments suitable to counteract or slow down ageing. Finally, this panel produced a consensus statement to highlight the importance of ageing, longevity and exceptional longevity, since this is a rapidly increasing phenotype worldwide. We acknowledge that not all experts in this field may completely agree with this statement.
Current Vascular Pharmacology
Title:Editorial: Ageing, Longevity, Exceptional Longevity and Related Genetic and Non Genetics Markers: Panel Statement
Volume: 12 Issue: 5
Author(s): Peter Avery, Nir Barzilai, Athanase Benetos, Helen Bilianou, Miriam Capri, Calogero Caruso, Claudio Franceschi, Niki Katsiki, Dimitri P. Mikhailidis, George Panotopoulos, Ewa Sikora, Irene P. Tzanetakou and Genovefa Kolovou
Affiliation:
Abstract: In May 2012, a group of scientists and clinicians met in Athens (Greece) to consider the relevance of ageing, longevity, exceptional longevity and related genetic and non genetic markers. During this meeting, we firstly reviewed recent epidemiological and clinical studies on ageing, longevity and exceptional longevity, briefly analyzed the ageing theories and discussed successful and unsuccessful ageing also taking into account the evolutionary perspective. Secondly, we considered the three phenotypes based on the definition of ageing, longevity and exceptional longevity and the associated biomarkers. Third, we discussed proposed treatments suitable to counteract or slow down ageing. Finally, this panel produced a consensus statement to highlight the importance of ageing, longevity and exceptional longevity, since this is a rapidly increasing phenotype worldwide. We acknowledge that not all experts in this field may completely agree with this statement.
Export Options
About this article
Cite this article as:
Avery Peter, Barzilai Nir, Benetos Athanase, Bilianou Helen, Capri Miriam, Caruso Calogero, Franceschi Claudio, Katsiki Niki, Mikhailidis P. Dimitri, Panotopoulos George, Sikora Ewa, Tzanetakou P. Irene and Kolovou Genovefa, Editorial: Ageing, Longevity, Exceptional Longevity and Related Genetic and Non Genetics Markers: Panel Statement, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161111666131219101226
DOI https://dx.doi.org/10.2174/1570161111666131219101226 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Exogenous Heparin-Derivative Affords Protection Against Lipid Anomalies and Apoptotic DNA Damage in Experimental Atherogenesis
Vascular Disease Prevention (Discontinued) Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension:Where Do We Go from Here?
Reviews on Recent Clinical Trials Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Lipoprotein (a) Management: Lifestyle and Hormones
Current Medicinal Chemistry Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Synthesis, Antioxidant and Anti-inflammatory Properties of an Apocynin- Derived Dihydrocoumarin
Medicinal Chemistry Editorial (Hot Topic: Treatment of Atherosclerosis as an Inflammatory Disease)
Current Pharmaceutical Design Therapeutic Angiogenesis for Limb Ischemia Using Angiogenic Growth Factors and Carriers
Current Tissue Engineering (Discontinued) Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation
Current Medicinal Chemistry Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach
Current Pharmaceutical Design In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Letters in Drug Design & Discovery Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Chronic Pain: Cytokines, Lymphocytes and Chemokines
Inflammation & Allergy - Drug Targets (Discontinued) Hemodynamic Regulation of Metallopeptidases within the Vasculature
Protein & Peptide Letters